Literature DB >> 9546104

Ontogenetic limb bone scaling in basic fibroblast growth factor (FGF-2) transgenic mice.

P S Lightfoot1, R Swisher, J D Coffin, T C Doetschman, R Z German.   

Abstract

Basic fibroblast growth factor (FGF-2) is a potent mitogen which is required for normal development, particularly the development of the skeletal system, where the inhibition of FGF binding to its receptor results in various skeletal malformations. The present study employed a newly engineered line of FGF-2 transgenic mice to determine the effects of overexpressing FGF-2 on limb bone ontogeny. We collected radiographic and weight data longitudinally and obtained the length, proximal, distal, and minimum diaphyseal widths of the humerus, femur, and tibia. Because growth is nonlinear with respect to time, we used the Gompertz mathematical model to obtain parameters describing rate and timing for each individual for each measurement. Differences in the parameters due to genotype and sex were subsequently tested with ANOVA. Transgenic animals exhibited consistently shorter limb bones which were generally wider at the epiphyses than those of controls. Parameters of early growth, including initial size and proportional rate of growth, appeared to be most directly responsible for significant differences in final size; however, exponential decay of growth was also a marginally significant factor. There were no differences between the genotypes in body weight, indicating that the shape anomalies observed in transgenic mice were a direct result of the action of FGF-2 rather than a general runting phenomenon.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9546104

Source DB:  PubMed          Journal:  Growth Dev Aging        ISSN: 1041-1232


  1 in total

1.  Human stanniocalcin-1 or -2 expressed in mice reduces bone size and severely inhibits cranial intramembranous bone growth.

Authors:  Jennifer Johnston; Yudith Ramos-Valdes; Lee-Anne Stanton; Sadia Ladhani; Frank Beier; Gabriel E Dimattia
Journal:  Transgenic Res       Date:  2010-02-20       Impact factor: 2.788

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.